Back

Glucose lowering drugs with proven cardiovascular benefit following acute coronary syndrome in type 2 diabetes: treatment gaps and outcomes

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Obesity and diabetes: risk assessment and prognosis Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Ibrahim Naoum

Lady Davis Carmel Medical Center, Haifa (Israel)

4 More presentations in this session

Presentation thumbnail
Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study
Doctor M. Lassen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Cardiovascular disease risk in people with diabetes in the era of universal diabetes screening
Miss J. Liang (Auckland, NZ)
Abstract Slides Video
Presentation thumbnail
Prognostic outcomes of masld and obesity in acute myocardial infarction
Doctor G. Kong (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Interleukin-6 and suPAR improves prediction of all-cause mortality in type 1 diabetes - the Thousand & 1 Study
Doctor H. Bahrami (Herlev, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity and diabetes: risk assessment and prognosis
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources